EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that members of management will participate in a fireside chat hosted by Cantor Fitzgerald Analyst Brian Cheng on Wednesday, December 8, 2021 at 1:00 p.m. ET.
The live call is reserved for institutional clients of Cantor Fitzgerald. A replay of the webcast can be accessed from the Investor Relations section of the company's website at www.immunome.com. The webcast replay will be available at the conclusion of the live presentation for approximately 30 days.
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company’s initial focus is developing therapeutics to treat oncology and infectious diseases, including COVID-19. Immunome’s proprietary discovery engine identifies novel therapeutic antibodies and their targets by leveraging the highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information, please visit www.immunome.com.
This press release and the referenced presentation may include “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, as amended. These forward looking statements may include, but not be limited to, statements about the execution of Immunome’s regulatory, clinical and strategic plans and achievement of future milestones for IMM-BCP-01 as and when planned; expectations regarding the design, attributes and therapeutic potential and benefits of IMM-BCP-01, including its anticipated neutralizing and clearance activity against Omicron and other emerging variants; our ability to obtain and maintain regulatory approvals for IMM-BCP-01; and our ability to continue development of IMM-BCP-01 as and when planned.
Forward-looking statements may be identified by the words “anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,” “could,” “should,” “seek,” “potential” and similar expressions. The forward-looking statements in this press release are based on Immunome’s current expectations, are neither promises nor guarantees, and you should not place undue reliance on them because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Immunome’s control, that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with the following: the impact of the COVID-19 pandemic on Immunome’s business, operations, strategy, goals and anticipated milestones; Immunome’s ability to execute on its R&D strategy; the effectiveness of IMM-BCP-01, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for its advancement; Immunome’s ability to fund operations; Immunome’s reliance on vendors; the competitive landscape; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Immunome’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in Immunome’s form 10-Q filings and other filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of the date of this press release, and Immunome specifically disclaims any intention or duty to update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as required under applicable law.